KaliVir Immunotherapeutics raises $14M
KaliVir Immunotherapeutics announced a Series A round of $14M on 19 August 2026. The company operates in HealthTech and is based in United States. It was founded by Helena Chaye, CEO. Announced 44 days ago.
Founder
Helena Chaye
CEO, KaliVir Immunotherapeutics
Outreach angles
- -Chaye leads KaliVir Immunotherapeutics as it advances its proprietary Vaccinia Enhanced Template platform through clinical development.
- -She is steering the company's lead candidate, VET3-TGI, through the STEALTH-001 Phase 1/1b trial in patients with advanced solid tumors.
- -The $14M extension brings KaliVir's Series A to $25M total, funding both monotherapy and atezolizumab-combination arms of the trial.
Signals
Series ADeep TechHealthcareRegulated IndustryB2B
Round details
Company: KaliVir Immunotherapeutics
Domain: kalivir.com
Amount: $14M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 19 August 2026
Other HealthTech raises
Recently funded in United States